Simcere Pharmaceutical Group Ltd

Price Chart

Risk-Adjusted Performance

Simcere Pharmaceutical Group Ltd (2096) Price Performance

Simcere Pharmaceutical Group Ltd (2096) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at HKD11.19, down 2.86% from the previous close.

Over the past year, 2096 has traded between a low of HKD7.18 and a high of HKD14.80. The stock has gained 49.9% over this period. It is currently 24.4% below its 52-week high.

Simcere Pharmaceutical Group Ltd has a market capitalization of $31.07B, with a price-to-earnings ratio of 29.32 and a dividend yield of 1.33%.

About Simcere Pharmaceutical Group Ltd

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN simnotrelvir tablets and ritonavir tablets. The company also offers promotional services for pharmaceutical products. In addition, it engages in the manufacture of pharmaceutical ingredients and its property management business. The company was founded in 1995 and is headquartered in Nanjing, China.